USPTO Examiner O DELL DAVID K - Art Unit 1621

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18706706METHODS FOR PREPARING DIHYDROXYAMMONIUM 5,5'-BISTETRAZOLE-1,1'DIOLATEMay 2024January 2025Allow910NoNo
18583627SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAMEFebruary 2024April 2025Allow1411NoNo
18442417NOVEL PROCESS FOR THE PREPARATION TAVABOROLE AND ITS INTERMEDIATESFebruary 2024February 2025Abandon1211NoNo
184377024-PHENYLPIPERIDINES, THEIR PREPARATION AND USEFebruary 2024March 2025Allow1310NoNo
183998612-PHENYL-3,4-DIHYDROPYRROLO[2,1 -F] [1,2,4]TRIAZINONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND USES THEREOFDecember 2023March 2025Allow1410YesNo
18395979METHODS FOR THE SYNTHESIS OF DEUTERATED DEXTROMETHORPHANDecember 2023March 2025Allow1410NoNo
18516560MODULATORS OF TNF-ALPHA ACTIVITYNovember 2023February 2025Allow1521NoNo
18511586UROLITHIN DERIVATIVES AND METHODS OF USE THEREOFNovember 2023March 2025Allow1611NoNo
18511627UROLITHIN DERIVATIVES AND METHODS OF USE THEREOFNovember 2023March 2025Allow1611NoNo
18388041METHODS FOR THE SYNTHESIS OF DEUTERATED DEXTROMETHORPHANNovember 2023December 2024Allow1410YesNo
18497181SYNTHESIS OF CANTHARIDINOctober 2023September 2024Allow1101NoNo
183842414-(4,5-BIS(4-BROMOPHENYL)-2-(4-METHOXYPHENYL)-1H-IMIDAZOL-1-YL)BUTANOIC ACID AS AN ANTIMICROBIAL COMPOUNDOctober 2023February 2024Allow310NoNo
18379125N'-(2-(5-PHENYL-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)-2- NAPHTHIMIDAMIDE AS ANTIMICROBIAL COMPOUNDOctober 2023March 2024Allow510NoNo
18371282Lipid Disulfide Prodrugs and Uses Related TheretoSeptember 2023April 2025Allow1910NoNo
18232198OXOPYRIDINE DERIVATIVES USEFUL AS AMINOCARBOXYMUCONATE SEMIALDEHYDE DECARBOXYLASE (ACMSD) INHIBITORSAugust 2023June 2025Allow2221YesNo
18228452COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITYJuly 2023June 2025Abandon2220NoNo
18348913BUTYL-BRIDGED DIPHOSPHINE LIGANDS FOR ALKOXYCARBONYLATIONJuly 2023December 2024Abandon1820NoNo
18216669(CYANO-DIMETHYL-METHYL)-ISOXAZOLES AND -[1,3,4]THIADIAZOLESJune 2023February 2025Allow2010NoNo
18344594HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASEJune 2023November 2024Abandon1701NoNo
18313428PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITORMay 2023November 2024Abandon1910NoNo
18296151CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOFApril 2023September 2024Allow1711YesNo
18129857BISACYL DIGERMANIUM COMPOUNDS, THEIR PREPARATION AND THEIR USE AS PHOTOINITIATOR FOR RADICAL POLYMERIZATIONApril 2023October 2024Abandon1921NoNo
18175956CARBORANE HYDROXAMIC ACID MATRIX METALLOPROTEINASE INHIBITORS AND AGENTS FOR BORON NEUTRON CAPTURE THERAPYFebruary 2023May 2024Allow1510NoNo
18153947BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORSJanuary 2023June 2024Allow1710YesNo
18093704TARGETED NITROXIDE AGENTSJanuary 2023May 2024Abandon1610NoNo
18013069THIOBENZOPYRANS AND THEIR USE IN PREPARATION OF DRUGS FOR TREATMENT OF RHEUMATOID ARTHRITISDecember 2022July 2024Allow1910YesNo
18146242TYK2 INHIBITORS AND USES THEREOFDecember 2022September 2024Abandon2101NoNo
18087302HETEROCYCLIC NMDA ANTAGONISTSDecember 2022July 2023Allow710YesNo
18145315OXABOROLE ESTERS AND USES THEREOFDecember 2022December 2024Abandon2401NoNo
18085341POLYETHYLENE GLYCOL DERIVATIVE AND USE THEREOFDecember 2022September 2024Allow2121NoNo
18081715METHOD FOR PURIFYING ETHYLENE CARBONATE THROUGH DYNAMIC CRYSTALLIZATIONDecember 2022March 2024Allow1520NoNo
18081842USE OF MORPHINAN DERIVATIVES FOR TREATMENT OF OPIOID DELTA RECEPTOR AGONIST-RELATED DISEASEDecember 2022April 2024Allow1610NoNo
18079790CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAMEDecember 2022March 2025Allow2721NoNo
18057020PROTEASOME ACTIVITY ENHANCING COMPOUNDSNovember 2022January 2025Allow2620YesNo
18056089NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND METHODS FOR USE OF THE SAMENovember 2022February 2024Allow1501NoNo
17983051PREPARATION OF SUFENTANIL CITRATE AND SUFENTANIL BASENovember 2022March 2025Allow2930YesNo
17974613TYROSINE KINASE INHIBITORSOctober 2022February 2025Abandon2721NoNo
17971804HOST-TARGETED PAN-RESPIRATORY ANTIVIRAL SMALL MOLECULE THERAPEUTICSOctober 2022January 2024Allow1511YesNo
17966227MYC-MAX INHIBITOR COMPOUND THERAPEUTICS FOR CANCER TREATMENT, METHODS AND USES ASSOCIATED THEREWITHOctober 2022February 2024Allow1611NoNo
17962781SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASESOctober 2022March 2024Allow1710NoNo
17937210COMPOUNDS AND METHODS FOR DETECTION OF NITRIC OXIDESeptember 2022October 2023Allow1201NoNo
17933434DIARYL MACROCYCLE POLYMORPHSeptember 2022August 2024Allow2311YesNo
17907972METHOD FOR PREPARING NEAR-INFRARED REGION II FLUORESCENT SMALL MOLECULEAugust 2022August 2024Allow2420NoNo
17877498Aminosteroids for the Treatment of a PTP1B Associated DiseaseJuly 2022March 2024Abandon1901NoNo
17869226ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITYJuly 2022December 2023Allow1712YesNo
178639414-CARBOXAMIDO-ISOINDOLINONE DERIVATIVES AS SELECTIVE PARP-1 INHIBITORSJuly 2022May 2023Allow1010NoNo
17864133COMPOUNDS FOR THE MODULATION OF MYC ACTIVITYJuly 2022March 2024Abandon2001NoNo
17861567MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATORJuly 2022October 2024Abandon2711NoNo
17853755HETEROCYCLIC GLP-1 AGONISTSJune 2022November 2023Allow1710NoNo
17737580SSAO INHIBITORS AND USE THEREOFMay 2022January 2024Allow2111NoNo
17730438SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORSApril 2022August 2023Allow1611NoNo
17730463SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORSApril 2022February 2024Allow2220NoNo
17726807MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETOApril 2022January 2024Allow2111NoNo
17720229TRYPTAMINE ANALOGUESApril 2022February 2024Abandon2231YesNo
17702597ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOFMarch 2022December 2023Abandon2101NoNo
17655630PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASESMarch 2022August 2023Abandon1701NoNo
17697981THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTSMarch 2022June 2023Allow1511YesNo
17687654NOVEL ANTI-OXIDANT COMPOUNDS AND COMPOSITIONSMarch 2022September 2023Abandon1911NoNo
17685709DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOFMarch 2022July 2024Allow2931YesNo
17665104DERIVATIVES OF RESIQUIMODFebruary 2022April 2024Allow2720NoNo
17592422LACTAMS AS CBL-B INHIBITORSFebruary 2022November 2024Abandon3421NoNo
17649744GPR84 ANTAGONISTS AND USES THEREOFFebruary 2022February 2025Allow3741YesNo
17586294UROLITHIN DERIVATIVES AND METHODS OF USE THEREOFJanuary 2022August 2023Allow1821YesNo
17582150IMIDAZOQUINOLINE DERIVATIVES AND THEIR USE IN THERAPYJanuary 2022March 2024Abandon2621NoNo
17582176IMIDAZOQUINOLINE DERIVATIVES AND THEIR USE IN THERAPYJanuary 2022March 2024Abandon2511NoNo
17578309SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAMEJanuary 2022October 2023Allow2111NoNo
17568824Aza (Indole)-, Benzothiophene-, And Benzofuran-3-SulfonamidesJanuary 2022June 2023Allow1711NoNo
17624134BENZOTHIOPHENE, THIENOPYRIDINE AND THIENOPYRIMIDINE DERIVATIVES FOR THE MODULATION OF STINGDecember 2021March 2025Allow3901YesNo
17560997COMPOSITIONS AND METHODS RELATED TO DI-SUBSTITUTED BICYCLO[2.2.1] HEPTANAMINE-CONTAINING COMPOUNDSDecember 2021July 2023Allow1911NoNo
175590516-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORSDecember 2021March 2024Allow2721YesNo
17556700RNA VIRUS INHIBITOR COMPOUNDS AND USES THEREOFDecember 2021July 2023Abandon1910NoNo
17554284CDK Inhibitors And Their Use As PharmaceuticalsDecember 2021June 2024Allow3021YesNo
17547254PREPARATION METHOD OF RACEMIC NICOTINEDecember 2021January 2025Allow3700NoNo
175479832-PHENYL-3,4-DIHYDROPYRROLO[2,1 -F] [1,2,4]TRIAZINONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND USES THEREOFDecember 2021September 2023Allow2211NoNo
17596341METHODS FOR PREPARING CANNABINOIDS BY BASE-PROMOTED DOUBLE-BOND MIGRATIONDecember 2021June 2025Abandon4201NoNo
17616748BIARYL DIALKYL PHOSPHINE OXIDE FPR2 AGONISTSDecember 2021February 2025Abandon3811NoNo
17614473SYNTHESIS METHOD FOR 1-METHYL-1H-INDAZOLE-6-CARBOXYLIC ACIDNovember 2021December 2024Allow3710NoNo
17612302PYRIDINIUM SALT AND PEST CONTROL AGENTNovember 2021May 2025Abandon4201NoNo
17612127ORGANIC TRANSISTOR MATERIAL AND ORGANIC TRANSISTORNovember 2021May 2025Allow4211NoNo
17521155FLUOROLACTONE AND METHOD FOR PRODUCING SAMENovember 2021May 2024Allow3021NoNo
17520287CARDIOPATHY-REDUCING PHOSPHODIESTER LIPIDSNovember 2021April 2023Allow1711NoNo
17452928METHODS OF MANUFACTURING OF NIRAPARIBOctober 2021November 2022Allow1300NoNo
17506331Aza (Indole)-, Benzothiophene-, And Benzofuran-3-SulfonamidesOctober 2021April 2023Allow1820NoNo
17505745PYRAZOLE AMINE REACTIVE CRYSTALLIZATIONOctober 2021July 2023Allow2110NoNo
17603536METHOD FOR PRODUCING CIS-(-)-FLOCINO PIPERIDOLOctober 2021January 2025Allow4030NoNo
17500039PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOROctober 2021June 2023Abandon2010NoNo
17593643INDOLE ALKALOID COMPOUND IN NONI ENZYME AND PREPARATION METHOD AND APPLICATION THEREOFSeptember 2021February 2025Allow4011NoNo
17441287METHOD FOR SYNTHESIZING LACTAM DERIVATIVES WITHOUT USE OF CATALYSTSeptember 2021September 2023Allow2411NoNo
17479838PROCESS FOR PREPARING 5-[[4-[2-[5-(1-HYDROXYETHYL)-2-PYRIDINYL]ETHOXY]PHENYL]-METHYL]-2,4-THIAZOLIDINEDIONE AND SALTS THEREOFSeptember 2021March 2023Allow1810NoNo
17476028COMPOUNDS AS NEUROKININ-1 RECEPTOR ANTAGONISTS AND USES THEREOFSeptember 2021September 2023Allow2410NoNo
17473032L-Dopa Enhanced with a Neuroprotective Agent as a Therapy for Parkinson's DiseaseSeptember 2021July 2023Abandon2211NoNo
17435606SYNTHESIS OF 4-AMINO-5-METHYL-1H-PYRIDIN-2(1H)-ON (INTERMEDIATE COMPOUND FOR THE SYNTHESIS OF THE MR ANTAGONIST FINERENONE) FROM 2-CHLORO-5-METHYL-4-NITRO-PYRIDINE-1-OXIDE USING THE INTERMEDIATE COMPOUND 2-CHLORO-5-METHYL-4-PYRIDINAMINESeptember 2021March 2025Allow4310NoNo
17434004COMPOUNDAugust 2021August 2023Abandon2401NoNo
17407278METHODS OF PREPARATION OF AMINOBORANES AND APPLICATIONS FOR BORYLATION AND SUZUKI COUPLINGAugust 2021April 2024Abandon3221NoNo
17401892PROCESS FOR THE PREPARATION OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILEAugust 2021July 2023Allow2310NoNo
17400772METHODS AND SYSTEMS FOR PRODUCTION OF FURFURALAugust 2021July 2025Abandon4720YesYes
17430426HERBICIDAL COMPOSITIONSAugust 2021January 2025Abandon4101NoNo
17398257FLUOROLACTONE AND METHOD FOR PRODUCING SAMEAugust 2021June 2025Allow4641YesNo
17398155NOVEL (CYANO-DIMETHYL-METHYL)-ISOXAZOLES AND -[1,3,4]THIADIAZOLESAugust 2021March 2023Allow2010NoNo
17390497Compounds for Treating Tauopathies and Restless Leg Syndrome and Methods of Using and Screening for SameJuly 2021May 2024Abandon3421NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner O DELL, DAVID K.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
9
Examiner Affirmed
7
(77.8%)
Examiner Reversed
2
(22.2%)
Reversal Percentile
34.0%
Lower than average

What This Means

With a 22.2% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
30
Allowed After Appeal Filing
12
(40.0%)
Not Allowed After Appeal Filing
18
(60.0%)
Filing Benefit Percentile
62.6%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 40.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner O DELL, DAVID K - Prosecution Strategy Guide

Executive Summary

Examiner O DELL, DAVID K works in Art Unit 1621 and has examined 353 patent applications in our dataset. With an allowance rate of 82.4%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 30 months.

Allowance Patterns

Examiner O DELL, DAVID K's allowance rate of 82.4% places them in the 48% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by O DELL, DAVID K receive 1.72 office actions before reaching final disposition. This places the examiner in the 50% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by O DELL, DAVID K is 30 months. This places the examiner in the 39% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +16.2% benefit to allowance rate for applications examined by O DELL, DAVID K. This interview benefit is in the 60% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 29.2% of applications are subsequently allowed. This success rate is in the 45% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 56.4% of cases where such amendments are filed. This entry rate is in the 78% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 40.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 34% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 70.0% of appeals filed. This is in the 51% percentile among all examiners. Of these withdrawals, 66.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 49.0% are granted (fully or in part). This grant rate is in the 58% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 9.9% of allowed cases (in the 96% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.5% of allowed cases (in the 80% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.